FIGURE 3 from Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma

Synergistic interaction between decitabine and tolinapant in reducing viability of TCL cell lines in vitro. Viability data obtained using CTG in H9 cells (A and B) and in BW5147 cells (C and D) after 3 days of treatment with a combination of decitabine and tolinapant (A and C) raw data and (B and D) HSA score from ComBenefit synergy analysis. E, Heat map showing a change in AUC measurements obtained from 3-day CTG assays in five different human TCL cell lines, testing the combination of tolinapant and decitabine (for raw data, see Supplementary Fig. S5). F, Cytotox-NIR signal captured by real-time microscopy (IncuCyte), detecting membrane permeabilization after the treatment of H9 cells with 1 µmol/L tolinapant, 1 µmol/L decitabine, or a combination of both.